Last updated: April 25, 2026
Depomed Inc. v. Watson Laboratories Inc. (Fla.) | Litigation Summary & Patent-Use Analysis
What is the case and where is it filed?
Depomed Inc. v. Watson Laboratories Inc. is a federal patent dispute filed in the U.S. District Court for the Southern District of Florida under case number 1:13-cv-00342. The case is captioned Depomed Inc. v. Watson Laboratories Inc. (Florida). The “Watson” defendant is Watson Laboratories Inc. (fka Watson Pharma-related entities across generic/ANDA matters), litigating over alleged infringement tied to Depomed’s drug IP.
What is the procedural posture?
The case is indexed as 1:13-cv-00342 in the federal docket. It is a litigation matter between the same parties as other ANDA-related IP disputes involving opioid and controlled-release product formulations (Depomed’s core area of patenting historically centers on controlled-release pain management products). The docket number indicates a 2013 filing year, consistent with the Depomed-era expansion of controlled-release IP enforcement tied to FDA generic entry pressures.
File and docket anchor
- Court: U.S. District Court (Southern District of Florida)
- Case number: 1:13-cv-00342
- Parties: Depomed Inc. (plaintiff) vs. Watson Laboratories Inc. (defendant)
What patents and infringement theories are at issue?
This record requires citation-level detail to produce a complete and accurate litigation summary. The provided input contains only the case caption and docket number. Without the asserted patent list, claim construction orders, summary judgment posture, and final judgment or dismissal terms, any attempt to name specific patents, asserted claims, or theories would risk fabricating infringement content.
Result: No complete, proof-backed mapping of asserted patents, written description or enablement disputes, prosecution history estoppel, inequitable conduct allegations, or equivalency arguments can be produced from the provided data alone.
How do the parties typically frame these disputes (high-level issue map)?
In Depomed v. generic-labeling controlled-release matters filed in this period, disputes typically cluster into these buckets:
- ANDA Paragraph IV / Orange Book: Whether the generic product infringes listed Depomed patents and whether listed patents are invalid.
- Claim construction: Whether critical formulation and release-profile terms require the same limitations in the accused product.
- Infringement proof: Whether the accused formulation meets the claim elements for drug release rate, matrix or coating structure, and controlled-release performance.
- Invalidity: Prior art anticipation/obviousness and lack of novelty tied to known controlled-release technologies.
- Remedies: Injunction and damages, or dismissal if patents are not asserted in a given procedural stage.
Result: A complete analysis cannot be grounded to this specific docket without docket orders and the asserted-patent set.
Litigation Timeline (What can be stated from the provided identifier)
Filing
- 2013: Case opened as 1:13-cv-00342 (Depomed Inc. v. Watson Laboratories Inc.).
Disposition
No disposition information (settlement terms, dismissal, claim drops, summary judgment grants/denials, or final judgment) is available in the provided input.
Result: No date-specific event timeline (Markman, dispositive motions, trial, final judgment) can be produced without docket extracts.
Patent-Use Analysis for Business Decisions
What is the business risk profile implied by this docket?
Based on the parties and the Depomed-controlled-release enforcement pattern in this era, the risk profile generally tracks three business questions:
- Is the asserted IP tied to formulation or to performance characteristics?
Formulation patents tend to create harder product-specific barriers, while performance-claim patents create test-and-structure arguments that often turn on expert sampling and release testing.
- How likely is early claim narrowing at Markman?
If the district court construes key terms narrowly, generic entry risk can fall quickly.
- How enforceable is the patent set under invalidity pressure?
Obviousness and anticipation outcomes often determine whether the litigation translates into enforceable barriers or collapses into settlement.
Result: This docket’s specific answer to each question cannot be derived from the provided input alone.
Actionable Due-Diligence Checklist (Based on what must exist in the record)
A litigation-ready patent-use analysis for this specific case requires the following docket artifacts:
- Asserted patent list (patent numbers) and asserted claim numbers.
- Claim construction order(s) and the court’s construction of key terms.
- Infringement contentions and product testing framework (drug release profile, formulation parameters, manufacturing details).
- Invalidity contentions (prior art references, expert summaries, anticipation/obviousness theories).
- Procedural outcomes (dismissals, summary judgment rulings, settlement orders).
No such artifacts are present in the supplied data, so no hard conclusions can be issued.
Key Takeaways
- The case is Depomed Inc. v. Watson Laboratories Inc., S.D. Florida, case number 1:13-cv-00342, filed in 2013.
- The provided input does not include asserted patents, claim constructions, dispositive rulings, or settlement/final disposition terms, so a proof-backed litigation summary of the merits cannot be produced.
- A credible business-grade patent-use analysis for this docket depends on docket orders and the asserted-patent set; those details are not available in the provided material.
FAQs
1) What court handled Depomed Inc. v. Watson Laboratories Inc.?
It is filed in U.S. District Court (Southern District of Florida) under 1:13-cv-00342.
2) What is the case number for this litigation?
1:13-cv-00342.
3) Who are the parties?
Depomed Inc. is the plaintiff; Watson Laboratories Inc. is the defendant.
4) Was the dispute tied to ANDA-related patent challenges?
The docket identifier and party profile align with Depomed’s typical enforcement pattern against generics, but the record provided does not confirm ANDA-specific mechanics for this exact case.
5) What are the immediate next steps to evaluate infringement and validity exposure?
Review: asserted patent list and claims, claim construction order, infringement contentions and testing results, and invalidity contentions and prior art record.
References
[1] U.S. District Court, Southern District of Florida. Depomed Inc. v. Watson Laboratories Inc., No. 1:13-cv-00342.
